TY - JOUR T1 - First-in-human PET imaging and estimated radiation dosimetry of L-[5-<sup>11</sup>C]-glutamine in patients with metastatic colorectal cancer JF - Journal of Nuclear Medicine JO - J Nucl Med DO - 10.2967/jnumed.120.261594 SP - jnumed.120.261594 AU - Allison S Cohen AU - Joe Grudzinski AU - Gary T. Smith AU - Todd E. Peterson AU - Jennifer G. Whisenant AU - Tiffany L. Hickman AU - Kristen K. Ciombor AU - Dana Cardin AU - Cathy Eng AU - Laura W. Goff AU - Satya Das AU - Robert J. Coffey AU - Jordan D. Berlin AU - Henry Charles Manning Y1 - 2021/04/01 UR - http://jnm.snmjournals.org/content/early/2021/04/30/jnumed.120.261594.abstract N2 - Altered metabolism is a hallmark of cancer. In addition to glucose, glutamine is an important nutrient for cellular growth and proliferation. Non-invasive imaging via positron emission tomography (PET) may help facilitate precision treatment of cancer through patient selection and monitoring of treatment response. L-[5-11C]-glutamine (11C-glutamine) is a PET tracer designed to study glutamine uptake and metabolism. The aim of this first-in-human study was to evaluate the radiologic safety and biodistribution of 11C-glutamine for oncologic PET imaging. Methods: Nine patients with confirmed metastatic colorectal cancer underwent PET/computed tomography (CT) imaging. Patients received 337.97 ± 44.08 MBq of 11C-glutamine. Dynamic PET acquisitions centered over the abdomen or thorax were initiated simultaneously with intravenous tracer administration. Following the dynamic acquisition, a whole-body PET/CT was acquired. Volume-of-interest analyses were carried out to obtain estimates of organ-based absorbed doses of radiation. Results: 11C-glutamine was well-tolerated in all patients with no observed safety concerns. Organs with the highest radiation exposure included the bladder, pancreas, and liver. The estimated effective dose was 4.46E-03 ± 7.67E-04 mSv/MBq. Accumulation of 11C-glutamine was elevated and visualized in lung, brain, bone, and liver metastases, suggesting utility for cancer imaging. Conclusion: PET using 11C-glutamine appears safe for human use and allows non-invasive visualization of metastatic colon cancer lesions in multiple organs. Further studies are needed to elucidate its potential for other cancers and for monitoring response to treatment. ER -